Patent ID: 11951120
Assignee: NANJING GENELEAP BIOTECHNOLOGY CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 13:
14. The mRNA of claim 13, wherein the at least one modified or non-naturally occurring nucleotide comprises at least one base modification,
where the at least one base modification is selected from the group consisting of: 2-amino-6-chloropurine riboside 5′ triphosphate, 2-aminoadenosine 5′ triphosphate, 2-thiocytidine 5′ triphosphate, 2-thiouridine 5′ triphosphate, 4-thiouridine 5′ triphosphate, 5-aminoallylcytidine 5′ triphosphate, 5-aminoallyluridine 5′ triphosphate, 5-bromocytidine 5′ triphosphate, 5-bromouridine 5′ triphosphate, 5-iodocytidine 5′ triphosphate, 5-iodouridine 5′ triphosphate, 5-methylcytidine 5′ triphosphate, 5-methyluridine 5′ triphosphate, 6-azacytidine 5′ triphosphate, 6-azauridine 5′ triphosphate, 6-chloropurine riboside 5′-triphosphate, 7-deazaadenosine 5′ triphosphate, 7-deazaguanosine 5′ triphosphate, 8-azaadenosine 5′ triphosphate, 8-azidoadenosine 5′ triphosphate, benzimidazole riboside 5′ triphosphate, N1-methyladenosine 5′ triphosphate, N1-methylguanosine 5′ triphosphate, N6-methyladenosine 5′ triphosphate, O6-methylguanosine 5′ triphosphate, N1-methyl-pseudouridine 5′ triphosphate, puromycin 5′-triphosphate, xanthosine 5′ triphosphate, and pseudouridine 5′triphosphate.